Skip to main content

Market Overview

RedHill Biopharma Expands Opaganib Global COVID-19 Study To US

  • Following the FDA review of data from the U.S. Phase 2 study of opaganib and receipt of its recommendations, RedHill Biopharma Ltd (NASDAQ: RDHLplans to expand its global Phase 2/3 study of opaganib in patients with severe COVID-19 to the U.S.
  • The study's expansion to the U.S. will help further speed-up enrollment, expand the study to eight countries and approximately 40 recruiting sites. The 464-patient study is over 50% enrolled, and topline data expected in the second quarter of 2021.
  • The global Phase 2/3 study recently underwent a positive DSMB futility review, which is suggestive that the study has the potential for a positive outcome.
  • In December last year, the company announced positive topline data from the non-powered U.S. Phase 2 study with opaganib in patients with COVID-19 pneumonia and demonstrated positive safety and efficacy signals.
  • Opaganib is an orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated antiviral, anti-inflammatory, and anti-thrombotic activity that targets a human cell component involved in viral replication.
  • Price Action: RDHL shares are down 3.0397% at $10.95 in the premarket trading on the last check Tuesday.

Related Articles (RDHL)

View Comments and Join the Discussion!

Posted-In: Covid-19Biotech News Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at